CymaBay Therapeutics Inc (DELISTED) (CBAY:DL)
32.48
0.00 (0.00%)
USD |
NASDAQ |
Mar 25, 16:00
CymaBay Therapeutics Research and Development Expense (TTM): 80.80M for Dec. 31, 2023
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 80.80M |
| September 30, 2023 | 74.28M |
| June 30, 2023 | 69.78M |
| March 31, 2023 | 68.13M |
| December 31, 2022 | 68.00M |
| September 30, 2022 | 70.17M |
| June 30, 2022 | 71.72M |
| March 31, 2022 | 70.58M |
| December 31, 2021 | 64.54M |
| September 30, 2021 | 56.82M |
| June 30, 2021 | 47.56M |
| March 31, 2021 | 38.76M |
| December 31, 2020 | 35.88M |
| September 30, 2020 | 46.13M |
| June 30, 2020 | 61.58M |
| March 31, 2020 | 74.76M |
| December 31, 2019 | 83.84M |
| September 30, 2019 | 79.30M |
| June 30, 2019 | 73.96M |
| March 31, 2019 | 67.24M |
| December 31, 2018 | 58.12M |
| Date | Value |
|---|---|
| September 30, 2018 | 48.40M |
| June 30, 2018 | 34.73M |
| March 31, 2018 | 24.37M |
| December 31, 2017 | 18.94M |
| September 30, 2017 | 16.12M |
| June 30, 2017 | 15.47M |
| March 31, 2017 | 15.55M |
| December 31, 2016 | 15.94M |
| September 30, 2016 | 16.14M |
| June 30, 2016 | 17.14M |
| March 31, 2016 | 17.27M |
| December 31, 2015 | 17.03M |
| September 30, 2015 | 18.25M |
| June 30, 2015 | 17.57M |
| March 31, 2015 | 17.40M |
| December 31, 2014 | 15.82M |
| September 30, 2014 | 11.91M |
| June 30, 2014 | 8.764M |
| March 31, 2014 | 5.65M |
| December 31, 2013 | 4.525M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
35.88M
Minimum
Dec 2020
83.84M
Maximum
Dec 2019
65.08M
Average
69.78M
Median
Jun 2023
Research and Development Expense (TTM) Benchmarks
| Gilead Sciences Inc | 8.222B |
| Assure Holdings Corp | -- |
| Societal CDMO Inc (DELISTED) | -- |
| AN2 Therapeutics Inc | 54.87M |
| Madrigal Pharmaceuticals Inc | 272.35M |